Step Back From That Overnight Triple, Sir

When a company produces data as good as Sarepta Therapeutics (Nasdaq: SRPT  ) did with its Duchenne muscular dystrophy drug, eteplirsen, it's hard not to get excited. There are no real options for patients, so reversing the decline is rather remarkable.

That being said, whenever everyone is giddy about a stock is usually the best time to take a step back and access the true risk. Here are some things investors should be worried about:

  • There are only four patients in each of the treatment groups. The true efficacy can only be seen with larger numbers. Of course, the treatment effect is so large, there's a lot of leeway for the effect to contract and still be positive in a larger trial.
  • The lower 30mg dose had a higher level of distrophin-positive fibers than the higher dose, but didn't show a statistically significant difference on the walk test. The simple answer is that two patients in that group had a rapid decline and couldn't walk well, but the data are certainly not as clean as one would hope. (They never are.)
  • At the higher dose, patients walked an average of 27 additional meters compared to baseline, but how does that break down among the four patients? If it's rather evenly distributed, that's great, but if there were one or two super-responders and the drug didn't help the others at all, the potential market for eteplirsen could be smaller.
  • Is the phase 2 data enough to get accelerated approval by the Food and Drug Administration? Getting onto the market early changes the valuation significantly since a phase 3 trial might not start for a year while Sarepta scales up manufacturing, and then it would take a year to complete.

There's no doubt that if these data hold up, eteplirsen will be approved. An 89-meter increase relative to placebo is remarkable for a six-minute walk test in drugs for conditions that affect walking. PTC Therapeutics' Ataluren, which treats Duchenne muscular dystrophy, produced a 30-meter increase, while Sanofi (NYSE: SNY  ) and BioMarin Pharmaceuticals (Nasdaq: BMRN  ) Aldurazyme, Shire's (Nasdaq: SHPG  ) Elaprase, and Sanofi's Myozyme -- which all treat rare diseases -- increased walking ability by 28 meters to 38 meters compared to placebo.

With a market cap less than $1 billion, I don't think Sarepta is particularly overpriced, even taking the risks into account, but if you're going to buy at this level, you have to be counting on an accelerated approval. Otherwise, it could be years before you see another major increase in the stock price like we've seen today.

Quick overnight triples are great, but it's the slow and steady companies that are often best for your retirement portfolio. Fool analysts have some suggestions in a new free report, "3 Stocks That Will Help You Retire Rich." You can claim your free copy by clicking here now.

Fool contributor Brian Orelli has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2042614, ~/Articles/ArticleHandler.aspx, 9/22/2014 10:22:36 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement